Certain Medications and Smoking Cessation Can Protect Ocular MG From Becoming Generalized, Study Says
Treatment with immunosuppressive agents and Mestinon (pyridostigmine) protects against transition from ocular myesthenia gravis (MG) to a…
José holds a BSc in Biochemistry and a PhD in Neuroscience from the University of Porto, in Portugal, and did post-docs in the U.S. and Canada (Weill Cornell Medicine and Western University, respectively) while still in academia. He joined Bionews in 2017 as a science writer and became a managing science editor in 2019. At Bionews, he has been able to cover the latest news related to multiple disease communities, while also doing interviews and covering several meetings. He is an author of 20 peer-reviewed papers and two book chapters. Topics of his research included the brain mechanisms implicated in Alzheimer’s disease, hypertension, and menopause. He also is a professor at the School of Health, Polytechnic of Porto.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Treatment with immunosuppressive agents and Mestinon (pyridostigmine) protects against transition from ocular myesthenia gravis (MG) to a…
Assessing altered eye movements with a technique called electrooculography (EOG) may become a non-invasive method for early diagnosis of…
Analyzing microbial and metabolic changes in fecal samples may provide a highly reliable way to diagnose myasthenia gravis (MG)…
Treatment with synthetic RNA molecules targeting the C5 complement system protein in the liver may be effective in people with…
Treatment with subcutaneous immunoglobulin (SCIg) — a new formulation given as an under-the-skin injection — enabled people with…
A recent report described a rare case of a woman presenting with a sudden decrease in voice volume who was…
Soliris (eculizumab) may be the most effective and well-tolerated immunotherapy for patients with myasthenia gravis (MG), according…
A vast majority of patients with myasthenia gravis (MG) responded to treatment with plasma exchange and half experienced…
Treatment with Soliris (eculizumab) provided adults with generalized myasthenia gravis (gMG) clinically meaningful improvements through three years…
Treatment of juvenile myasthenia gravis (JMG) lessens the severity of symptoms in most patients, leading to stable remission without…
Get regular updates to your inbox.